RESUMO
Providing and improving the care of patients suffering from lymphedema remains an essential goal for the clinical management of populations affected by lymphatic filariasis. Although the Essential Package of Care (EPC) recommended by the WHO leads to important positive benefits for many of these lymphedema patients, it is important to continue to address the challenges that remain both in quantifying these effects and in ensuring optimal care. This report, based on the authors' scientific and field experience, focuses on the impact and significance of lymphedema, its clinical presentation, current treatment approaches, and the importance of lymphedema care to the Global Program to Eliminate Lymphatic Filariasis. It emphasizes specific practical issues related to managing lymphedema, such as the importance of beginning treatment in the condition's early stages and the development of effective approaches to assess patients' progress toward improving both their clinical status and their overall quality of life. Priorities for research are also examined, particularly the need for tools to identify patients and to assess disease burden in endemic communities, the creation of EPC accessibility to as many patients as possible (i.e., targeting 100% "geographic coverage" of care), and the empowerment of patients to ensure the sustainability, and ultimately the provision of care from sectors of the national public health systems of endemic countries.
RESUMO
Lymphedema (LE) is one the most disfiguring chronic manifestations of lymphatic filariasis. Its management relies primarily on limb hygiene and local care. A previous study in Ghana demonstrating a beneficial effect of doxycycline on LE led to the current multicenter trial on the efficacy of doxycycline in filarial LE. A randomized placebo-controlled trial was initiated in two rural health districts in Mali. Patients with LE stages 1-3 were randomized to receive either doxycycline (200 mg/day) or placebo over a 6-week monitored treatment period and were then followed every 6 months for 2 years. Both groups received materials for limb hygiene that was carried out daily for the entire 2-year study. The primary endpoint was lack of progression in LE stage at 24 months. One hundred patients were enrolled in each study arm. The baseline sociodemographic characteristics of each group were largely similar. There was no significant difference at month 24 after treatment initiation in the number of subjects showing progression in LE stage between the two treatment arms (P = 0.5921). Importantly, however, the number of attacks of acute adenolymphangitis (ADLA) was reduced in both arms, but there was no significant difference between the two groups at any follow-up time point (all P >0.23). Doxycycline was well tolerated in those receiving the drug. When added to daily self-administered limb hygiene, a 6-week course of doxycycline (200 mg) was not superior to placebo in increasing the improvement associated with hygiene alone in LE volume, stage, or frequency of ADLA attacks over a 24-month period.
RESUMO
One of the oldest of the neglected tropical diseases, lymphatic filariasis, is caused by filarial worms transmitted by insect vectors that live in the lymphatic system and most commonly cause lymphedema, elephantiasis and hydrocele, which may lead to severe deformity, stigma and disability. Similar to other neglected tropical diseases, lymphatic filariasis occurs mostly among the poor disenfranchised populations living in highly endemic settings perpetuating a cycle that traps people into further poverty and destitution. Through the leadership of the World Health Organization, the Global Programme to Eliminate Lymphatic Filariasis has reached substantial achievements in decreasing the transmission of lympahtic filariasis in multiple settings. The strategic plan for the next 10 years of the Global Programme, in addition to working within the new 'neglected tropical diseases environment,' lays out necessary mass drug administration implementation goals for the filariasis-endemic countries that have not yet started their elimination programs (principally in Africa). The neglected tropical diseases programs-and the lymphatic filariasis program in particular-are among the very least expensive, most cost-effective tools to benefit needy populations of the developing world.